Literature DB >> 11040943

HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities.

D A Graham1, C S Herrington.   

Abstract

AIM: To test the hypothesis that, because the human papillomavirus (HPV) E2 protein represses viral early gene transcription, E2 gene sequence variation or disruption could play a part in the induction of the numerical chromosome abnormalities that have been described in squamous cervical lesions.
METHODS: The integrity and sequence of the E2 gene from 11 cervical intraepithelial neoplasia (CIN) grade 3 lesions and 14 invasive squamous cell carcinomas, all of which contained HPV-16, were analysed by the polymerase chain reaction (PCR). The E2 gene was amplified in three overlapping fragments and PCR products sequenced directly. Chromosome abnormalities were identified by interphase cytogenetics using chromosome specific probes for chromosomes 1, 3, 11, 17, 18, and X.
RESULTS: E2 gene disruption was present in significantly more invasive carcinomas (eight of 14) than CIN 3 lesions (one of 11) (p = 0.03). No association was found between E2 disruption and the presence of a numerical chromosome abnormality. The E2 gene from the non-disrupted isolates was sequenced and wild-type (n = 5) and variant (n = 11) sequences identified. Variant sequences belonged to European and African classes and contained from one to 15 amino acid substitutions. Although numerical chromosome abnormalities were significantly more frequent in invasive squamous cell carcinoma than CIN 3 (p = 0.04), there was no significant relation between the presence of sequence variation and either histological diagnosis or chromosome abnormality.
CONCLUSIONS: These data do not support the hypothesis that E2 gene disruption or variation is important in the induction of chromosome imbalance in these lesions. However, there is a relation between E2 gene disruption and the presence of invasive disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040943      PMCID: PMC1186970          DOI: 10.1136/mp.53.4.201

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  29 in total

1.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings.

Authors:  M V Jacobs; P J Snijders; A J van den Brule; T J Helmerhorst; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.

Authors:  T Yamada; M M Manos; J Peto; C E Greer; N Munoz; F X Bosch; C M Wheeler
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID.

Authors:  S H Tan; L E Leong; P A Walker; H U Bernard
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein.

Authors:  M G Frattini; S D Hurst; H B Lim; S Swaminathan; L A Laimins
Journal:  EMBO J       Date:  1997-01-15       Impact factor: 11.598

5.  Kinetic and equilibrium binding studies of the human papillomavirus type-16 transcription regulatory protein E2 interacting with core enhancer elements.

Authors:  C M Sanders; N J Maitland
Journal:  Nucleic Acids Res       Date:  1994-11-25       Impact factor: 16.971

6.  Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins.

Authors:  C M Chiang; M Ustav; A Stenlund; T F Ho; T R Broker; L T Chow
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

7.  Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes.

Authors:  R J Jewers; P Hildebrandt; J W Ludlow; B Kell; D J McCance
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer.

Authors:  J Dillner; F Wiklund; P Lenner; C Eklund; V Frederiksson-Shanazarian; J T Schiller; M Hibma; G Hallmans; U Stendahl
Journal:  Int J Cancer       Date:  1995-01-27       Impact factor: 7.396

9.  Lack of immortalizing activity of a human papillomavirus type 16 variant DNA with a mutation in the E2 gene isolated from normal human cervical keratinocytes.

Authors:  A Storey; I Greenfield; L Banks; D Pim; T Crook; L Crawford; M Stanley
Journal:  Oncogene       Date:  1992-03       Impact factor: 9.867

10.  Suppression of cellular proliferation by the papillomavirus E2 protein.

Authors:  J J Dowhanick; A A McBride; P M Howley
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  6 in total

1.  Correlation between physical status of human papilloma virus and cervical carcinogenesis.

Authors:  Kezhen Li; Xin Jin; Yong Fang; Changyu Wang; Mei Gong; Pingbo Chen; Jia Liu; Dongrui Deng; Jihui Ai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

2.  Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer.

Authors:  Hugo Arias-Pulido; Cheri L Peyton; Nancy E Joste; Hernan Vargas; Cosette M Wheeler
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

3.  The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma.

Authors:  Wei Li; Wei Wang; Mani Si; Linfei Han; Qinglei Gao; Aiyue Luo; Yan Li; Yunping Lu; Shixuan Wang; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-14       Impact factor: 4.553

4.  Integration of human papillomavirus type 16 in cervical cancer cells.

Authors:  Zivile Gudleviciene; Daiva Kanopiene; Ausra Stumbryte; Raminta Bausyte; Edgaras Kirvelaitis; Vaida Simanaviciene; Aurelija Zvirbliene
Journal:  Open Med (Wars)       Date:  2014-09-25

5.  Sequence variation in the E2-binding domain of HPV16 and biological function evaluation in Tunisian cervical cancers.

Authors:  Saloua Kahla; Lotfi Kochbati; Samia Hammami; Mohamed Badis Chanoufi; Mongi Maalej; Ridha Oueslati
Journal:  Biomed Res Int       Date:  2014-06-17       Impact factor: 3.411

6.  Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma.

Authors:  Nicole V Anayannis; Nicolas F Schlecht; Miriam Ben-Dayan; Richard V Smith; Thomas J Belbin; Thomas J Ow; Duk M Blakaj; Robert D Burk; Sarah M Leonard; Ciaran B Woodman; Joanna L Parish; Michael B Prystowsky
Journal:  PLoS One       Date:  2018-02-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.